SYRE Q3 2017 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+9.7% YoY

Gross Profit

$00.0% margin

Operating Income

-$8M-634.3% margin

Net Income

-$8M-624.4% margin

EPS (Diluted)

$-12.00

QoQ Revenue Growth

-14.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$728,000

Balance Sheet

Total Assets

$61M

Total Liabilities

$5M

Stockholders' Equity

$56M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+9.7%
Gross Profit	$0	$0	—
Operating Income	-$8M	-$6M	-26.9%
Net Income	-$8M	-$6M	-26.2%